

## 2 **Omicron infection of vaccinated individuals enhances neutralizing immunity** 3 **against the Delta variant**

4 Khadija Khan<sup>1,2#</sup>, Farina Karim<sup>1,2#</sup>, Sandile Cele<sup>1,2</sup>, James Emmanuel San<sup>3</sup>, Gila Lustig<sup>4</sup>, Houriiyah  
5 Tegally<sup>3,5</sup>, Yuval Rosenberg<sup>6</sup>, Mallory Bernstein<sup>1</sup>, Yashica Ganga<sup>1</sup>, Zesuliwe Jule<sup>1</sup>, Kajal Reedy<sup>1</sup>,  
6 Nokuthula Ngcobo<sup>1</sup>, Matilda Mazibuko<sup>1</sup>, Ntombifuthi Mthabela<sup>1</sup>, Zoey Mhlane<sup>1</sup>, Nikiwe Mbatha<sup>1</sup>,  
7 Yoliswa Miya<sup>1</sup>, Jennifer Giandhari<sup>3</sup>, Yajna Ramphal<sup>3</sup>, Taryn Naidoo<sup>1</sup>, Nithendra Manickchund<sup>7</sup>,  
8 Nombulelo Magula<sup>8</sup>, Salim S. Abdool Karim<sup>4,9</sup>, Glenda Gray<sup>10</sup>, Willem Hanekom<sup>1,11</sup>, Anne von  
9 Gottberg<sup>12,13</sup>, , COMMIT-KZN Team<sup>§</sup>, Ron Milo<sup>6</sup>, Bernadett I. Gosnell<sup>7</sup>, Richard J. Lessells<sup>3,4</sup>, Penny L.  
10 Moore<sup>4,12,13,14</sup>, Tulio de Oliveira<sup>3,4,5,15</sup>, Mahomed-Yunus S. Moosa<sup>7</sup>, Alex Sigal<sup>1,2,16\*</sup>

11 <sup>1</sup>Africa Health Research Institute, Durban, South Africa. <sup>2</sup>School of Laboratory Medicine and Medical  
12 Sciences, University of KwaZulu-Natal, Durban, South Africa. <sup>3</sup>KwaZulu-Natal Research Innovation  
13 and Sequencing Platform, Durban, South Africa. <sup>4</sup>Centre for the AIDS Programme of Research in  
14 South Africa, Durban, South Africa. <sup>5</sup>Centre for Epidemic Response and Innovation, School of Data  
15 Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.  
16 <sup>6</sup>Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.  
17 <sup>7</sup>Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of  
18 KwaZulu-Natal, Durban, South Africa. <sup>8</sup>Department of Internal Medicine, Nelson R. Mandela School  
19 of Medicine. University of Kwa-Zulu Natal. <sup>9</sup>Department of Epidemiology, Mailman School of Public  
20 Health, Columbia University, New York, NY, United States. <sup>10</sup>South African Medical Research Council,  
21 Cape Town, South Africa. <sup>11</sup>Division of Infection and Immunity, University College London, London,  
22 UK. <sup>12</sup>National Institute for Communicable Diseases of the National Health Laboratory Service,  
23 Johannesburg, South Africa. <sup>13</sup>SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty  
24 of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. <sup>14</sup>Institute of  
25 Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.  
26 <sup>15</sup>Department of Global Health, University of Washington, Seattle, USA. <sup>16</sup>Max Planck Institute for  
27 Infection Biology, Berlin, Germany.

28 # Equal contribution.

29 \* Corresponding author. Email: [alex.sigal@ahri.org](mailto:alex.sigal@ahri.org)

30 **Omicron variant (B.1.1.529) infections are rapidly expanding worldwide, often in settings where the**  
31 **Delta variant (B.1.617.2) was dominant. We investigated whether neutralizing immunity elicited by**  
32 **Omicron infection would also neutralize the Delta variant and the role of prior vaccination. We**  
33 **enrolled South African participants infected with Omicron a median of 5 days post-symptoms onset**  
34 **(study baseline) with a last follow-up sample taken a median of 23 days post-symptoms onset. Some**  
35 **participants were unvaccinated while others were breakthrough cases vaccinated with Pfizer**  
36 **BNT162b2 or Johnson and Johnson Ad26.CoV2.S. In vaccinated participants, neutralization of**  
37 **Omicron increased 13.7-fold over baseline. This compared to a 4.4-fold increase in unvaccinated**  
38 **individuals. Over the same period, Delta virus neutralization was enhanced 6.6-fold in vaccinated**  
39 **but only 2.5-fold in unvaccinated participants. Moreover, vaccinated participants were able to**  
40 **mount a stronger neutralization response against Delta relative to Omicron virus. This was not the**  
41 **case in unvaccinated individuals, some of whom continued to show low Delta neutralization, and**  
42 **contrasted sharply with poor cross-neutralization of Omicron in Delta infected persons. Higher**  
43 **Omicron neutralization in vaccinated individuals may enable a more effective immune response to**  
44 **Omicron, while enhancement of Delta neutralization should lead to lower Delta re-infections. Given**  
45 **emerging data indicating Omicron is less pathogenic than Delta, such an outcome may have**  
46 **implications in terms of decreasing Covid-19 severe disease.**

47

48 The Omicron variant of SARS-CoV-2, first identified in November 2021 in South Africa and Botswana<sup>1</sup>,  
49 has been shown by us<sup>2</sup> and others<sup>3-8</sup> to have extensive but incomplete escape from immunity elicited  
50 by vaccines and previous infection, with boosted individuals showing better neutralization. In South  
51 Africa, Omicron infections led to a lower incidence of severe disease relative to other variants<sup>9,10</sup>,  
52 although this can be at least partly explained by pre-existing immunity<sup>2</sup>. While Omicron infections are  
53 rising steeply, many countries still have high levels of Delta variant infection. How Delta and Omicron  
54 will interact is still unclear. One possibility is that Omicron and Delta will coexist, and another is that  
55 Omicron will curtail the spread of Delta by eliciting a neutralizing immune response against Delta in  
56 Omicron convalescents, so that Delta could not effectively re-infect.

57 We investigated whether Omicron infection elicits neutralizing immunity to the Delta virus. We  
58 isolated Omicron virus without the R346K mutation from an infection in South Africa (see Table S1 for  
59 detailed genotypic information of the viral isolate used). We neutralized this isolate with plasma from  
60 participants enrolled during the Omicron infection wave in South Africa, with each participant having  
61 a confirmed diagnosis of SARS-CoV-2 by qPCR. To quantify neutralization, we used a live virus  
62 neutralization assay and calculated the focus reduction neutralization test (FRNT<sub>50</sub>) value, the inverse  
63 of the plasma dilution required for 50% neutralization, as measured by the reduction in the number  
64 of infection foci. We enrolled 25 participants late November and December 2021. Two participants  
65 had advanced HIV disease based on a low CD4 count (<50 cells/uL) and unsuppressed HIV infection.  
66 Our previous data indicated an atypical response to SARS-CoV-2 infection in advanced HIV disease<sup>11</sup>  
67 and we excluded the two participants from this analysis. Table S2 summarizes the characteristics of  
68 the remaining 23 participants.

69 Fourteen out of 23 participants were admitted to hospital because of Covid-19 symptoms, but only  
70 one required supplemental oxygen. Ten participants were vaccinated and had a breakthrough  
71 Omicron infection. Five were vaccinated with two doses of Pfizer-BNT162b2 and 5 with Johnson and  
72 Johnson Ad26.CoV2.S, with one Ad26.CoV2.S vaccinee being boosted with a second Ad26.CoV2.S dose  
73 (Table S3). Out of the 23 participants, only 3 (1 vaccinated and 2 unvaccinated) self-reported having a  
74 previous SARS-CoV-2 infection (Table S3). Participants were sampled at enrollment, which was a  
75 median of 5 days (interquartile range 3-8 days) post-symptom onset, and again at weekly follow-up  
76 visits which were attended as practicable because of the Christmas holidays in South Africa. The last  
77 follow-up visit was a median of 23 days (interquartile range 17-25 days) post-symptom onset (Table  
78 S2). Virus from the upper respiratory tract from each participant was sampled using a combined  
79 nasopharyngeal and oropharyngeal swab, and all viruses successfully sequenced were confirmed to  
80 be Omicron (Table S3).

81 We analyzed neutralization at enrollment (baseline for the study) and the last follow-up visit. We  
82 observed that Omicron neutralization increased in vaccinated individuals from a low geometric mean  
83 titer (GMT) FRNT<sub>50</sub> of 28 at the enrollment visit to FRNT<sub>50</sub> = 378 at last follow-up, a 13.7-fold increase  
84 (95% CI 3.8-49.5, Fig 1A). The samples from unvaccinated participants neutralized at a similar starting  
85 level at study baseline (FRNT<sub>50</sub> = 26) but reached a lower final level (FRNT<sub>50</sub> = 113) at last follow-up, a  
86 4.4-fold increase (95% CI 1.4-13.5, Fig 1B).

87 Neutralization of Delta virus increased during this period in the vaccinated individuals. At enrollment,  
88 neutralization capacity against Delta virus was higher than against Omicron (FRNT<sub>50</sub> = 129) and  
89 reached FRNT<sub>50</sub> = 790 at last follow-up, a 6.1-fold increase (95% CI 1.8-20.7, Fig 1C). The unvaccinated  
90 had lower Delta neutralization at baseline with Delta virus FRNT<sub>50</sub> = 18, and reached FRNT<sub>50</sub> = 46, a  
91 non-statistically significant 2.5-fold increase (95% CI 0.9-7.0, Fig 1D).

92 Comparing Omicron and Delta neutralization at the last available follow-up visit showed that  
93 vaccinated participants were able to mount a better neutralizing response against the Delta virus than  
94 against the Omicron virus: neutralization of Delta virus was 2.1-fold higher than Omicron (Fig 1E, 95%  
95 CI 1.5-2.9). In contrast, in unvaccinated participants, neutralization of Delta was 2.5-fold lower relative

96 to Omicron (95% CI 1.1-5.8), although this was not statistically significant because of the high  
97 variability between participant values (Fig 1F).

98 Examining neutralization at all available timepoints per study participant showed that neutralization  
99 of the Omicron variant seemed to peak approximately 2 weeks post-reported symptom onset date  
100 (Fig 2). The pattern in vaccinated individuals showed a high degree of uniformity, with a rise in  
101 Omicron neutralization capacity mirrored by a rise in Delta neutralization capacity in 9 out of 10  
102 vaccinated participants, and with Delta neutralization level very similar to or higher than Omicron  
103 neutralization level. In contrast, the pattern in unvaccinated participants was much more variable,  
104 with neutralization of Omicron visibly stronger than neutralization of Delta virus in 6 out of 13  
105 participants.

106 We also tested neutralization of Omicron by Delta variant elicited immunity. We collected 18 plasma  
107 samples from a group of 14 participants previously infected in the Delta variant wave in South Africa,  
108 some of whom were vaccinated either before or after infection (Table S4; for 4 of the vaccinated  
109 participants, a sample was available post-infection, and then again post-vaccination). Confirming  
110 previously reported results<sup>7</sup>, we observed extensive escape of the Omicron viral isolate used here  
111 from Delta elicited immunity across all samples tested. This was manifested as a 22.5-fold decrease  
112 (95% CI 14.4-35.0, Fig 3) of Omicron virus neutralization compared to Delta virus neutralization.

113 The variability in Delta virus neutralization enhancement which we observed in the responses of  
114 unvaccinated participants may be because of previous unreported infection in some individuals, which  
115 could potentially confer a degree of Delta immunity. However, sources of heterogeneity not related  
116 to previous SARS-CoV-2 infection history are also possible. In contrast, vaccinated participants all have  
117 previous SARS-CoV-2 immunity from vaccination. They showed a stronger rise in Omicron  
118 neutralization and stronger enhancement of immunity to the Delta variant relative to unvaccinated  
119 participants. The dependence of Delta neutralization enhancement on previous immunity may  
120 indicate that enhancement may rely on boosting previous SARS-CoV-2 immunity rather than elicit  
121 antibodies that can specifically recognize and neutralize both Omicron and Delta.

122 Vaccination leads to a lower hospitalization rate with Omicron infection  
123 (<https://www.discovery.co.za/corporate/health-insights-vaccines-real-world-effectiveness>). This may  
124 be because Omicron does not have extensive escape from other arms of the adaptive immune  
125 response<sup>12</sup> or because Omicron virus shows attenuated cell-to-cell spread<sup>13</sup> which leads to decreased  
126 lung infection and pathology<sup>14,15</sup>. A stronger neutralizing response after Omicron infection, as shown  
127 here in vaccinated participants, should also contribute to vaccine mediated protection against more  
128 severe disease with Omicron.

129 These results are consistent with Omicron displacing the Delta variant, since Omicron can elicit  
130 immunity which neutralizes Delta. In contrast, we have observed in this study and others have  
131 previously shown<sup>7</sup> that Omicron escapes neutralizing immunity elicited by Delta infection. This  
132 indicates that Omicron can re-infect Delta infected individuals but not vice-versa, giving Omicron an  
133 advantage over Delta. The implications of such displacement would depend on whether Omicron is  
134 indeed less pathogenic than Delta. If so, then the incidence of Covid-19 severe disease would be  
135 reduced and the infection may shift to become less disruptive to individuals and society.

136

137 **Materials and methods**

138 Informed consent and ethical statement

139 Blood samples were obtained after written informed consent from adults with PCR-confirmed SARS-  
140 CoV-2 infection who were enrolled in a prospective cohort study approved by the Biomedical Research  
141 Ethics Committee at the University of KwaZulu–Natal (reference BREC/00001275/2020). Use of  
142 residual swab sample for SARS-0CoV-2 isolation was approved by the University of the Witwatersrand  
143 Human Research Ethics Committee (HREC) (ref. M210752).

144 Data availability statement

145 Sequence of outgrown virus has been deposited in GISAID with accession EPI\_ISL\_7886688. Raw  
146 images of the data are available upon reasonable request.

147 Code availability

148 Curve fitting scripts in MATLAB v.2019b are available on GitHub  
149 (<https://github.com/sigallab/NatureMarch2021>).

150 Whole-genome sequencing, genome assembly and phylogenetic analysis

151 RNA was extracted on an automated Chemagic 360 instrument, using the CMG-1049 kit (Perkin Elmer,  
152 Hamburg, Germany). The RNA was stored at  $-80^{\circ}\text{C}$  prior to use. Libraries for whole genome  
153 sequencing were prepared using either the Oxford Nanopore Midnight protocol with Rapid Barcoding  
154 or the Illumina COVIDseq Assay. For the Illumina COVIDseq assay, the libraries were prepared  
155 according to the manufacturer’s protocol. Briefly, amplicons were tagged, followed by indexing  
156 using the Nextera UD Indexes Set A. Sequencing libraries were pooled, normalized to 4 nM and  
157 denatured with 0.2 N sodium acetate. A 8 pM sample library was spiked with 1% PhiX (PhiX Control  
158 v3 adaptor-ligated library used as a control). We sequenced libraries on a 500-cycle v2 MiSeq Reagent  
159 Kit on the Illumina MiSeq instrument (Illumina). On the Illumina NextSeq 550 instrument, sequencing  
160 was performed using the Illumina COVIDSeq protocol (Illumina Inc, USA), an amplicon-based next-  
161 generation sequencing approach. The first strand synthesis was carried using random hexamers  
162 primers from Illumina and the synthesized cDNA underwent two separate multiplex PCR reactions.  
163 The pooled PCR amplified products were processed for tagmentation and adapter ligation using IDT  
164 for Illumina Nextera UD Indexes. Further enrichment and cleanup was performed as per protocols  
165 provided by the manufacturer (Illumina Inc). Pooled samples were quantified using Qubit 3.0 or 4.0  
166 fluorometer (Invitrogen Inc.) using the Qubit dsDNA High Sensitivity assay according to manufacturer’s  
167 instructions. The fragment sizes were analyzed using TapeStation 4200 (Invitrogen). The pooled  
168 libraries were further normalized to 4nM concentration and 25  $\mu\text{L}$  of each normalized pool containing  
169 unique index adapter sets were combined in a new tube. The final library pool was denatured and  
170 neutralized with 0.2N sodium hydroxide and 200 mM Tris-HCL (pH7), respectively. 1.5 pM sample  
171 library was spiked with 2% PhiX. Libraries were loaded onto a 300-cycle NextSeq 500/550 HighOutput  
172 Kit v2 and run on the Illumina NextSeq 550 instrument (Illumina, San Diego, CA, USA). For Oxford  
173 Nanopore sequencing, the Midnight primer kit was used as described by Freed and Silander55. cDNA  
174 synthesis was performed on the extracted RNA using LunaScript RT mastermix (New England BioLabs)  
175 followed by gene-specific multiplex PCR using the Midnight Primer pools which produce 1200bp  
176 amplicons which overlap to cover the 30-kb SARS-CoV-2 genome. Amplicons from each pool were  
177 pooled and used neat for barcoding with the Oxford Nanopore Rapid Barcoding kit as per the  
178 manufacturer’s protocol. Barcoded samples were pooled and bead-purified. After the bead clean-up,  
179 the library was loaded on a prepared R9.4.1 flow-cell. A GridION X5 or MinION sequencing run was  
180 initiated using MinKNOW software with the base-call setting switched off. We assembled paired-end

181 and nanopore.fastq reads using Genome Detective 1.132 (<https://www.genomedetective.com>) which  
182 was updated for the accurate assembly and variant calling of tiled primer amplicon Illumina or Oxford  
183 Nanopore reads, and the Coronavirus Typing Tool<sup>56</sup>. For Illumina assembly, GATK HaploTypeCaller --  
184 min-pruning 0 argument was added to increase mutation calling sensitivity near sequencing gaps. For  
185 Nanopore, low coverage regions with poor alignment quality (<85% variant homogeneity) near  
186 sequencing/amplicon ends were masked to be robust against primer drop-out experienced in the  
187 Spike gene, and the sensitivity for detecting short inserts using a region-local global alignment of  
188 reads, was increased. In addition, we also used the wf\_artic (ARTIC SARS-CoV-2) pipeline as built using  
189 the nextflow workflow framework<sup>57</sup>. In some instances, mutations were confirmed visually with .bam  
190 files using Geneious software V2020.1.2 (Biomatters). The reference genome used throughout the  
191 assembly process was NC\_045512.2 (numbering equivalent to MN908947.3). For lineage  
192 classification, we used the widespread dynamic lineage classification method from the 'Phylogenetic  
193 Assignment of Named Global Outbreak Lineages' (PANGOLIN) software suite  
194 (<https://github.com/hCoV-2019/pangolin>)<sup>19</sup>. P2 stock was sequenced and confirmed Omicron with  
195 the following substitutions:  
196 E:T9I,M:D3G,M:Q19E,M:A63T,N:P13L,N:R203K,N:G204R,ORF1a:K856R,ORF1a:L2084I,ORF1a:A2710T,  
197 ORF1a:T3255I,ORF1a:P3395H,ORF1a:I3758V,ORF1b:P314L,ORF1b:I1566V,ORF9b:P10S,S:A67V,S:T95I  
198 ,S:Y145D,S:L212I,S:G339D,S:S371L,S:S373P,S:S375F,S:K417N,S:N440K,S:G446S,S:S477N,S:T478K,S:E4  
199 84A,S:Q493R,S:G496S,S:Q498R,S:N501Y,S:Y505H,S:T547K,S:D614G,S:H655Y,S:N679K,S:P681H,S:N76  
200 4K,S:D796Y,S:N856K,S:Q954H,S:N969K,S:L981F. Sequence was deposited in GISAID, accession:  
201 EPI\_ISL\_7886688.

## 202 Cells

203 Vero E6 cells (ATCC CRL-1586, obtained from Cellonex in South Africa) were propagated in complete  
204 growth medium consisting of Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine  
205 serum (Hyclone) containing 10mM of HEPES, 1mM sodium pyruvate, 2mM L-glutamine and 0.1mM  
206 nonessential amino acids (Sigma-Aldrich). Vero E6 cells were passaged every 3–4 days. H1299 cell lines  
207 were propagated in growth medium consisting of complete Roswell Park Memorial Institute (RPMI)  
208 1640 medium with 10% fetal bovine serum containing 10mM of HEPES, 1mM sodium pyruvate, 2mM  
209 L-glutamine and 0.1mM nonessential amino acids. H1299 cells were passaged every second day. The  
210 H1299-E3 (H1299-ACE2, clone E3) cell line was derived from H1299 (CRL-5803) as described in our  
211 previous work<sup>2,16</sup>.

## 212 Virus expansion

213 All work with live virus was performed in Biosafety Level 3 containment using protocols for SARS-CoV-  
214 2 approved by the Africa Health Research Institute Biosafety Committee. ACE2-expressing H1299-E3  
215 cells were seeded at  $4.5 \times 10^5$  cells in a 6 well plate well and incubated for 18–20 h. After one DPBS  
216 wash, the sub-confluent cell monolayer was inoculated with 500  $\mu$ L universal transport medium  
217 diluted 1:1 with growth medium filtered through a 0.45- $\mu$ m filter. Cells were incubated for 1 h. Wells  
218 were then filled with 3 mL complete growth medium. After 4 days of infection (completion of passage  
219 1 (P1)), cells were trypsinized, centrifuged at 300 rcf for 3 min and resuspended in 4 mL growth  
220 medium. Then all infected cells were added to Vero E6 cells that had been seeded at  $2 \times 10^5$  cells per  
221 mL, 20mL total, 18–20 h earlier in a T75 flask for cell-to-cell infection. The coculture of ACE2-expressing  
222 H1299-E3 and Vero E6 cells was incubated for 1 h and the flask was filled with 20 mL of complete  
223 growth medium and incubated for 4 days. The viral supernatant from this culture (passage 2 (P2)  
224 stock) was used for experiments.

225

226

## 227 Live virus neutralization assay

228 H1299-E3 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day pre-infection.  
229 Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 min and  
230 stored at  $-80^{\circ}\text{C}$ . Aliquots of plasma samples were heat-inactivated at  $56^{\circ}\text{C}$  for 30 min and clarified by  
231 centrifugation at 10,000 rcf for 5 min. Virus stocks were used at approximately 50-100 focus-forming  
232 units per microwell and added to diluted plasma. Antibody-virus mixtures were incubated for 1 h at  
233  $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$ . Cells were infected with 100  $\mu\text{L}$  of the virus-antibody mixtures for 1 h, then 100  $\mu\text{L}$  of  
234 a 1X RPMI 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay  
235 was added without removing the inoculum. Cells were fixed 18 h post-infection using 4% PFA (Sigma-  
236 Aldrich) for 20 min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12,  
237 GenScript A02058) at 0.5  $\mu\text{g}/\text{mL}$  in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich),  
238 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in PBS. Plates were incubated with  
239 primary antibody overnight at  $4^{\circ}\text{C}$ , then washed with wash buffer containing 0.05% Tween-20 in PBS.  
240 Secondary goat anti-rabbit HRP conjugated antibody (Abcam ab205718) was added at 1  $\mu\text{g}/\text{mL}$  and  
241 incubated for 2 h at room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-  
242 0030) was then added at 50  $\mu\text{L}$  per well and incubated for 20 min at room temperature. Plates were  
243 imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot Professional  
244 built-in image analysis (C.T.L).

## 245 Statistics and fitting

246 All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization data  
247 were fit to:

$$248 \quad T_x = 1 / (1 + (D / ID_{50}))$$

249 Here  $T_x$  is the number of foci normalized to the number of foci in the absence of plasma on the same  
250 plate at dilution  $D$  and  $ID_{50}$  is the plasma dilution giving 50% neutralization.  $FRNT_{50} = 1 / ID_{50}$ . Values of  
251  $FRNT_{50} < 1$  are set to 1 (undiluted), the lowest measurable value. We note that the most concentrated  
252 plasma dilution was 1:25 and therefore  $FRNT_{50} < 25$  were extrapolated.

## 253 Acknowledgements

254 This study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of  
255 Health award R01 AI138546 (AS), and South African Medical Research Council awards (AS, TdO, PLM)  
256 and the UK Foreign, Commonwealth and Development Office and Wellcome Trust (Grant no  
257 221003/Z/20/Z, PLM). PLM is also supported by the South African Research Chairs Initiative of the  
258 Department of Science and Innovation and the NRF (Grant No 98341). The funders had no role in study  
259 design, data collection and analysis, decision to publish, or preparation of the manuscript.

## 260 References

- 261 1 Viana, R. *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern  
262 Africa. *Nature*, doi:doi: <https://doi.org/10.1038/d41586-021-03832-5> (2021).
- 263 2 Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.  
264 *Nature*, doi:doi: <https://doi.org/10.1038/d41586-021-03824-5> (2021).
- 265 3 Andrews, N. *et al.* Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529)  
266 variant of concern. *medRxiv*, 2021.2012.2014.21267615, doi:10.1101/2021.12.14.21267615  
267 (2021).
- 268 4 Garcia-Beltran, W. F. *et al.* mRNA-based COVID-19 vaccine boosters induce neutralizing  
269 immunity against SARS-CoV-2 Omicron variant. *medRxiv*, 2021.2012.2014.21267755,  
270 doi:10.1101/2021.12.14.21267755 (2021).

271 5 Cao, Y. *et al.* B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse  
272 epitopes. *bioRxiv*, 2021.2012.2007.470392, doi:10.1101/2021.12.07.470392 (2021).

273 6 Lu, L. *et al.* Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or  
274 Coronavac vaccine recipients. *medRxiv*, 2021.2012.2013.21267668,  
275 doi:10.1101/2021.12.13.21267668 (2021).

276 7 Rössler, A., Riepler, L., Bante, D., Laer, D. v. & Kimpel, J. SARS-CoV-2 B.1.1.529 variant  
277 (Omicron) evades neutralization by sera from vaccinated and convalescent individuals.  
278 *medRxiv*, 2021.2012.2008.21267491, doi:10.1101/2021.12.08.21267491 (2021).

279 8 Planas, D. *et al.* Considerable escape of SARS-CoV-2 variant Omicron to antibody  
280 neutralization. *bioRxiv*, 2021.2012.2014.472630, doi:10.1101/2021.12.14.472630 (2021).

281 9 Wolter, N. *et al.* Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant  
282 in South Africa. *medRxiv*, 2021.2012.2021.21268116, doi:10.1101/2021.12.21.21268116  
283 (2021).

284 10 Davies, M.-A. *et al.* Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-  
285 driven fourth wave compared with previous waves in the Western Cape Province, South  
286 Africa. *medRxiv*, 2022.2001.2012.22269148, doi:10.1101/2022.01.12.22269148 (2022).

287 11 Cele, S. *et al.* SARS-CoV-2 evolved during advanced HIV disease immunosuppression has  
288 Beta-like escape of vaccine and Delta infection elicited immunity. *medRxiv (Accepted Cell  
289 Host & Microbe)*, doi:10.1101/2021.09.14.21263564 (2021).

290 12 Keeton, R. *et al.* SARS-CoV-2 spike T cell responses induced upon vaccination or infection  
291 remain robust against Omicron. *medRxiv*, 2021.2012.2026.21268380,  
292 doi:10.1101/2021.12.26.21268380 (2021).


293 13 Meng, B. *et al.* SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell  
294 fusion. *bioRxiv*, 2021.2012.2017.473248, doi:10.1101/2021.12.17.473248 (2021).

295 14 McMahan, K. *et al.* Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters.  
296 *bioRxiv*, 2022.2001.2002.474743, doi:10.1101/2022.01.02.474743 (2022).

297 15 Bentley, E. G. *et al.* SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than  
298 Pango B and Delta variants strains in a mouse model of severe COVID-19. *bioRxiv*,  
299 2021.2012.2026.474085, doi:10.1101/2021.12.26.474085 (2021).


300 16 Cele, S. *et al.* Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.  
301 *Nature* **593**, 142-146, doi:10.1038/s41586-021-03471-w (2021).

302




**Figure 1: Enhancement of Delta neutralization by Omicron infection.** (A) Neutralization of Omicron virus by Omicron infection elicited plasma in n=10 convalescent vaccinated participants, (n=5 two doses of Pfizer BNT162b2, n=5 Johnson and Johnson Ad26.CoV2.S). Each participant was sampled at the initial enrollment visit (median 5 days post-symptom onset) and compared to the last follow-up visit (median 23 days post-symptom onset). Numbers are geometric mean titers (GMT) of the reciprocal plasma dilution (FRNT<sub>50</sub>) resulting in 50% neutralization. Fold-change is calculated by dividing the larger GMT value by the smaller value and arrows indicate direction of change between enrollment and follow-up. Dashed line is most concentrated plasma tested. (B) as in (A) for the n=13 unvaccinated participants. (C) Neutralization of Delta virus by Omicron infection elicited plasma in the vaccinated participants. (D) as in (C) for the unvaccinated participants. (E) Neutralization of Omicron compared to Delta virus by Omicron infection elicited plasma in vaccinated participants at the last follow-up visit. Arrow indicates direction of change between Omicron and Delta virus. (F) as in (E) for the unvaccinated participants. p-values were: (A)  $6.6 \times 10^{-4}$ , (B) 0.031, (C)  $2.3 \times 10^{-3}$ , (D) 0.15, (E) 0.032, (F) 0.79 as determined by the Wilcoxon rank sum test.





**Figure 2: Omicron and Delta neutralization capacity over time in Omicron infected participants.** Neutralization of Omicron (blue) and Delta (red) at all study visits. Participant number is as in Table S3. First row are Pfizer BNT162b2 vaccinated, second row are Johnson and Johnson Ad26.CoV2.S vaccinated, and bottom three rows are unvaccinated participants. X-axis is the time post-symptom onset when sample was collected, and y-axis is neutralization as FRNT<sub>50</sub>. Dashed line is the most concentrated plasma tested.



**Figure 3: Escape of Omicron virus from Delta infection elicited immunity.** Neutralization of Delta compared to Omicron virus by Delta infection elicited plasma immunity in vaccinated and unvaccinated participants. 18 samples were tested from n=14 participants infected during the Delta infection wave in South Africa (see Table S4). Dashed line is the most concentrated plasma tested. p-value is  $1.6 \times 10^{-7}$  as determined by the Wilcoxon rank sum test.

**Table S1: Read counts of majority and minority genotypes detected in outgrown virus used in experiments**

Amino Acid change	Nucleotide change	Codon change	Reads
<u>A67V</u>	21762C>T	21761 GCT>GTT	GCT – 45 GTT – 3134
<u>*H69_V70del</u>	21766_21771delACATGT	21766_21771ACATGT>del	ACATGT – 0 del – 1132
<u>T95I</u>	21846C>T	21845 ACT>ATT	ACT – 53 ATT – 2171
<u>*G142D</u>	21987_21989delGTG	21987_21989GTG >del	GTG – 0 del – 1572
<u>*V143_Y145del</u>	21990_21995delTTTATT	21990_21995TTTATT >del	TTTATT – 0 del – 1572
<u>*L212I</u>	22194_22196delATT	22194_22196ATT >del	ATT – 114 del – 2897
<u>*R214_D215</u>	22204_22205insGAGCCAGAA	22204_22205GAGCCAGAA >ins	WT – 808 insGAGCCAGAA – 1316
<u>G339D</u>	22578G>A	22577 GGT>GAT	GGT – 104 GAT – 3519
<u>S371L</u>	22674C>T	22674 TCC>CTC	TCC – 41 CTC – 1359
<u>S373P</u>	22679T>C	22679 TCA>CCA	TCA – 64 CCA – 1696
<u>S375F</u>	22686C>T	22685 TCC>TTC	TCC – 25 TTC – 1569
<u>K417N</u>	22813G>T	22811 AAG>AAT	AAG – 36 AAT – 1885
<u>N440K</u>	22882T>G	22880 AAT>AAG	AAT – 294 AAG – 1579
<u>G446S</u>	22898G>A	22898 GGT>AGT	GGT – 74 AGT – 1686
<u>S477N</u>	22992G>A	22991AGC>AAC	AGC – 18 AAC – 1917
<u>T478K</u>	22995C>A	22994ACA>AAA	ACA – 55 AAA – 1968
<u>E484A</u>	23013A>C	23012GAA>GCA	GAA – 32 GCA – 1903
<u>Q493R</u>	23040A>G	23039CAA>CGA	CAA – 4 CGA – 2060
<u>G496S</u>	23048G>A	23048GGT>AGT	GGT – 53 AGT – 1734
<u>Q498R</u>	23055A>G	23054CAA>CGA	CAA – 28 CGA – 1733
<u>N501Y</u>	23063A>T	23063AAT>TAT	AAT – 49 TAT – 1812
<u>Y505H</u>	23075T>C	23075TAC>CAC	TAC – 55 CAC – 1451
<u>T547K</u>	23202C>A	23201ACA>AAA	ACA – 10 AAA – 1655
<u>D614G</u>	23403A>G	23402GAT>GGT	GAT – 17 GGT – 1398
<u>H655Y</u>	23525C>T	23525CAT>TAT	CAT – 26 TAT – 1556
<u>N679K</u>	23599T>G	23597AAT>AAG	AAT – 21 AAG – 1245
<u>P681H</u>	23604C>A	23603CCT>CAT	CCT – 0 CAT – 535
<u>N764K</u>	23854C>A	23852AAC>AAA	AAC – 23 AAA – 290
<u>D796Y</u>	23948G>T	23948GAT>TAT	GAT – 8 TAT – 217
<u>N856K</u>	24130C>A	24128AAC>AAA	AAC – 9 AAA – 155
<u>Q954H</u>	24424A>T	24422CAA>CAT	CAA – 9 CAT – 298
<u>N969K</u>	24469T>A	24467AAT>AAA	AAT – 31 AAA – 392
<u>L981F</u>	24503C>T	24503CTT>TTT	CTT – 112 TTT – 347

\*Only deletions or insertions where the adjacent codon was preserved were counted. WT – Wild Type i.e reads without the insertion.

**Table S2: Summary characteristics of Omicron infected participants**

	All	Vaccinated	Unvaccinated
Number Participants	23	10	13
Age*	32 (26-37)	36 (33-36)	26 (26-34)
Male sex	10 (43%)	4 (40%)	6 (46%)
Days post-vaccination		140 (116-192)	
Days post-symptom onset to enrolment	5 (3-8)	4 (2-6)	7 (3-8)
Days post-symptom onset to last follow-up	23 (17-25)	23 (15-27)	22 (19-24)

\*Median (IQR).

**Table S3: Detailed characteristics of Omicron infected participants**

Participant #	Age	Sex	Vacc. type	Vacc. date	Days post-vacc. to enroll.	Date symptom onset	Ct enroll.	Symptoms onset to last follow-up	GISAID ID of infecting virus
1	30-39	M	AD26.COV	Mar-2021	278	Dec-2021*	25	23	
2	30-39	M	AD26.COV**	Mar-2021	264	Nov-2021	14	22	
3	50-59	F	BNT162b2	May-2021	200	Dec-2021	17	27	EPI_ISL_8604915
4	30-39	F	AD26.COV	May-2021	210	Dec-2021	31	13	EPI_ISL_8604910
5	20-29	F	AD26.COV	Sep-2021	89	Dec-2021	24	27	
6	10-19	F	BNT162b2	Jul-2021	157	Dec-2021	23	12	EPI_ISL_8604906
7	20-29	F	No			Nov-2021	UND	24	
8	30-39	M	No			Dec-2021	18	23	EPI_ISL_8604919
9	40-49	F	No			Dec-2021	32	28	EPI_ISL_8604901
10	20-29	M	No			Dec-2021	30	13	EPI_ISL_8604908
11	20-29	F	No			Dec-2021	28	22	EPI_ISL_8604913
12	20-29	F	No			Dec-2021*	UND	22	
13	30-39	M	BNT162b2	Jul-2021	129	Nov-2021	32	28	EPI_ISL_8604916
14	20-29	M	No			Nov-2021	31	15	
15	60-69	F	BNT162b2	May-2021	198	Dec-2021	25	25	EPI_ISL_8604920
16	60-69	M	BNT162b2	Dec-2021	15	Dec-2021	24	10	EPI_ISL_8578311
17	30-39	M	No			Dec-2021	37	19	EPI_ISL_8604923
18	60-69	F	No			Dec-2021#	27	23	EPI_ISL_8578312
19	30-39	M	No			Dec-2021*	31	27	EPI_ISL_8604924
20	20-29	F	No			Dec-2021	37	24	EPI_ISL_8604911
21	20-29	M	No			Dec-2021	28	21	EPI_ISL_8604922
22	30-39	F	AD26.COV	Aug-2021	120	Dec-2021	33	23	
23	20-29	F	No			Dec-2021	30	10	EPI_ISL_8604902

Ct enroll.: qPCR cycle threshold for SARS-CoV-2 at enrollment. UND: Undetectable. AD26.COV: Johnson and Johnson AD26.CoV.2 vaccine. \*Reported previous infection. \*\*Boosted with Ad26.CoV2.S in Nov-2021.#Required supplemental O<sub>2</sub>.

**Table S3: Detailed characteristics of Delta infected participants**

Participant #	Participant ID	Age	Sex	Vacc. type	Vacc. date	Days post-vaccination to collection	Date symptom onset	Ct enroll.	Symptom onset to collection	GISAID ID
1	02-0104	40-49	F				Jul-2021	26	26	EPI_ISL_3722338
2	02-0106	40-49	M				Jul-2021	31	23 <sup>#</sup>	EPI_ISL_3722335
3	02-0108	50-59	M				Jul-2021	30	31	
4	13-0140	50-59	M				Jun-2021	27	37	
5	13-0153	40-49	M				Jul-2021	35	44	
6	13-0157	30-39	M				Jul-2021	37	32	
7	02-0110	70-79	M	BNT162b2	Jun-2021	37	Jul-2021*	37	15	
8	13-0171	60-69	F	BNT162b2	Nov-2021	14	Aug-2021	UND	116	
9	02-0129	40-49	F	AD26.COV	May-2021	117	Jul-2021*	UND	31	
10	02-0140	50-59	F	AD26.COV	Apr-2021	147	Jul-2021*	UND	57	
11 Pre	02-0109	40-49	M				Aug-2021	35	13 <sup>#</sup>	
11 Post	02-0109	40-49	M	BNT162b2	Oct-2021	18				
12 Pre	13-0141	40-49	M				Jul-2021	23	24	EPI_ISL_3939068
12 Post	13-0141	40-49	M	AD26.COV	Sep-2021	32				
13 Pre	13-0142	30-39	M				Jul-2021	27	24	EPI_ISL_3939088
13 Post	13-0142	30-39	M	AD26.COV	Sep-2021	32				
14 Pre	13-0149	50-59	F				Jul-2021	27	23 <sup>#</sup>	EPI_ISL_3447779
14 Post	13-0149	50-59	F	BNT162b2	Oct-2021	22				

<sup>#</sup>Asymptomatic. Date of diagnostic swab used instead of symptoms onset. \*Breakthrough infection. Ct enroll.: qPCR cycle threshold for SARS-CoV-2 at enrollment. UND: Undetectable. AD26.COV: Johnson and Johnson AD26.CoV.2 vaccine. Pre: sample taken pre-vaccination. Post: sample taken post-vaccination for a participant with a pre-vaccination sample.